Table 1. Selected trials of neoadjuvant immunotherapy for NSCLC.

Trial identifier	Phase	Sponsor	Stage	Intervention	Primary endpoint
NCT02259621	2	Sidney Kimmel Comprehensive Cancer Center	IB–IIIA	Nivolumab with or without ipilimumab	Safety and feasibility
NCT02998528	3	BMS	IB–IIIA	Nivolumab and ipilimumab versus chemotherapy	MPR
NCT03158129	2	M.D. Anderson Cancer Center	I–IIIA	Nivolumab with or without ipilimumab	MPR
NCT02818920	2	Duke University Medical Center	IB–IIIA	Pembrolizumab (neoadjuvant and adjuvant)	Surgical feasibility rate
NCT02927301	2	LCMC-3, Genentech	IB–IIIA	Atezolizumab	MPR
NCT02572843		Swiss Group for Clinical Cancer Research	IIIA (N2)	Durvalumab	Event-free survival (EFS)
NCT03081689	2	Spanish Lung Cancer Group	IIIA (N2)	Nivolumab, carboplatin, paclitaxel	PFS

NSCLC, non-small cell lung cancer; BMS, Bristol Meyer Squibb; LCMC, Lung Cancer Mutation Consortium; MPR, major pathologic response rate.